10-K: United Health Products Files 10-K, Awaits FDA Decision on Hemostatic Gauze

United Health Products reports its 2023 financial results and provides an update on its FDA application for its hemostatic gauze product.

Summary

• United Health Products, Inc. (UHP) is focused on developing, manufacturing, and marketing its patented hemostatic gauze, HemoStyp.
• The company is seeking FDA Class III approval for surgical applications of HemoStyp, having submitted a revised application on March 21, 2024.
• UHP experienced a net loss of $2,623,267 in 2023, compared to a net loss of $1,687,501 in 2022.
• The company's revenue was $0 in 2023, down from $37,500 in 2022, as resources were focused on the FDA application.
• Operating expenses decreased to $2,426,539 in 2023 from $2,820,895 in 2022, primarily due to reduced legal and consulting costs.
• Research and development expenses were $598,810 in 2023, slightly down from $624,564 in 2022.
• The company has a negative working capital of $1,798,558 as of December 31, 2023.
• UHP is exploring strategic options, including potential partnerships, a sale or merger, or a standalone growth plan.
• The company has received approximately $2.7 million in proceeds from White Lion Capital, which has been used to fund operations and the FDA application process.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a lack of revenue, and substantial doubt about the company's ability to continue as a going concern. While there are positive aspects such as the FDA application and patent protection, the overall financial situation and risks outweigh the positives, resulting in a low sentiment score.

Positives

• The company has submitted a revised PMA application to the FDA, addressing previous deficiencies.
• HemoStyp is a natural substance derived from cotton, with no chemical additives, thrombin, collagen, or animal-derived products.
• Laboratory testing has shown HemoStyp to be 100% absorbable in the human body within 24 hours.
• The company has patents protecting its hemostatic gauze technology through 2029.
• UHP is exploring multiple strategic options to maximize shareholder value.
• The company has received funding from White Lion Capital to support operations and the FDA application process.

Negatives

• The company experienced a significant net loss of $2,623,267 in 2023.
• Revenue was $0 in 2023, indicating a lack of sales during the year.
• The company has a negative working capital of $1,798,558.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• There is no assurance that the FDA will approve the company's PMA application.

Risks

• The company has a history of operating losses and may continue to lose money in the future.
• There is no assurance that the FDA will approve the Class III application for internal surgical procedures.
• The company may not be able to penetrate target markets successfully.
• The company may not be able to secure additional financing to execute its business plan.
• The company's success depends on market acceptance of its hemostatic gauze products.
• The company may be dependent on commercial relationships to conduct its operations.
• The company could experience difficulties in its supply chain.
• The company is dependent on one hemostatic gauze product to generate income.
• The company may not be able to adequately protect its technologies or intellectual property rights.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The healthcare industry is subject to extensive government regulation, which can result in increased costs and delays.
• The company's stock price may be volatile.
• There is currently no established market for the company's common stock.

Future Outlook

The company is evaluating paths to rapidly grow revenue and profits in all potential market segments, with the objective of maximizing shareholder value. They are considering a sale or merger, or commercial partnerships. There is no assurance that any specific transaction will occur.

Management Comments

• Management believes that the Class III surgical markets represent the most attractive market for their products.
• Management is evaluating the best paths to grow revenue and profits, including commercial partnerships and licensing agreements.
• Management is focused on addressing deficiencies identified by the FDA in their PMA application.
• Management believes cybersecurity represents an important component of the company's overall approach to risk management and oversight.

Industry Context

The wound care market is dominated by large, established companies, making it challenging for smaller players like UHP to compete. The company is focusing on the Class III surgical market, which has fewer competitors and premium pricing, but requires regulatory approval.

Comparison to Industry Standards

• The company's hemostatic gauze product, HemoStyp, competes with products from large companies like Baxter International, Becton Dickinson & Company, and Johnson & Johnson.
• Unlike some competitors, HemoStyp is derived from cotton and contains no chemical additives, thrombin, collagen, or animal-derived products.
• HemoStyp is reported to be 100% absorbable in the human body within 24 hours, which is faster than some competing organic regenerated cellulose products.
• The company's focus on the Class III surgical market is a strategic move to target a less crowded and more profitable segment, but it requires FDA approval, which is a significant hurdle.
• The company's financial performance, with no revenue in 2023 and a significant net loss, is not comparable to the financial stability of larger, established competitors.

Legal Proceedings

• The company settled a lawsuit with Philip Forman by issuing 1,850,000 shares of common stock.
• The company settled an SEC investigation by paying a civil penalty of $450,000.
• The company settled a lawsuit with its former auditors for $392,000.

Related Party Transactions

• The company has convertible notes payable to related parties, including the CEO and a director.
• The company has loans payable to related parties, including the CEO and Principal Financial Officer.
• The company has accrued liabilities to related parties, including officers and management.
• The company issued shares of common stock to officers and management for compensation and to settle accrued liabilities.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity financings.
• Shareholders face the risk of losing their investment due to the company's financial instability.
• Employees and consultants may be impacted by the company's financial challenges.
• Customers may be impacted by the company's ability to bring its products to market.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to pursue FDA Class III approval for its HemoStyp product.
• The company will evaluate strategic options, including potential partnerships, a sale or merger, or a standalone growth plan.
• The company will continue to seek additional financing to fund its operations.
• The company will work to remediate the identified material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

hemostatic gauze, HemoStyp, FDA approval, Class III, surgical market, wound care, Premarket Approval, medical device, regulatory approval, intellectual property